HOME >> BIOLOGY >> NEWS
Microarray technology for tailoring breast cancer therapy

Microarray technology could be used to tailor therapy according to the individual, and prevent breast cancer patients from having to undergo painful unsuccessful therapies. In a study published in the journal Breast Cancer Research, researchers analysed tumour tissue samples and identified a group of 64 genes that can be used to predict a patient's response in the five years after adjuvant therapy for breast cancer. Identifying patients whose breast tumours express these genes could potentially be used to predict which patients would not benefit from adjuvant therapy, and avoid patients being given therapies with the potential of causing more harm than good.

A team of researchers led by Jonas Bergh from the Karolinska Institutet in Stockholm, Sweden, analysed the gene expression profiles of 159 breast cancer patients using DNA microarray analysis. From these samples they identified the genetic signatures shown by 38 patients who had a poor prognosis - defined as relapse or death from any cause within 5 years. The remaining 121 patients were defined as the 'good prognosis' group. The researchers also used gene expression profiling to separate patients who did well with and without adjuvant therapy, and those whose tumours failed to respond to treatment.

An analysis of the genes expressed in the tumours of all 159 patients showed that 64 genes were used to separate the patients with good and poor prognoses. The researchers then tested the predictive value of the group of 64 genes compared with three currently used clinical markers. Using the expression patterns of the 64 genes identified by the researchers gave significantly better (P=0.007) prediction rates than histological grading, tumour stage and age - which are all accepted prognostic markers for breast cancer.

The present lack of criteria to help tailor breast cancer treatment to individual patients indicates a need to develop new techniques for better prediction of how patients wi
'"/>

Contact: Prof Per Hall
per.hall@ki.se
46-73-625-0342
Karolinska Institutet
2-Oct-2005


Page: 1 2

Related biology news :

1. The Center of Nutrigenomics of the TU Munich licences Genomatix Microarray Analysis Pipeline
2. German Microarray Excellence Center integrates Genomatix Chip Analysis Pipeline
3. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible status
4. Microarrays as phenotype
5. AFCYBER holds science and technology symposium
6. New technology reveals seal behavior
7. Nanotechnology helps scientists make bendy sensors for hydrogen vehicles
8. FDA Nanotechnology Task Force takes positive step forward
9. Liverpool amongst first in UK to install unique DNA sequencing technology
10. EPA foregoes opportunity to improve nanotechnology oversight
11. The Cancer Genome Atlas awards funds for technology development

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Microarray technology for tailoring breast cancer therapy

(Date:11/6/2014)... PITTSBURGH--Speed is an asset for a predator. Except when that ... The tiger beetle, relative to its size, is the fastest ... 120 body lengths per second (at about five miles per ... To take the sprinting gold from the tiger beetle, a ... BUT! The tiger beetle has a problem. At peak speeds, ...
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
(Date:11/4/2014)...   3D scanner developer targets ... Fuel3D , a developer of 3D scanning solutions, today announced ... (£4 million). This funding builds on the company,s initial $2.6 ... the way for the commercial launch of the company,s consumer ... led by Chimera Partners and will be used to ramp-up ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
(Date:11/26/2014)... Nov. 26, 2014 The Alliance ... a survey of European physicians at the "1 ... and Biological Therapies" at the Spanish Ministry of ... by EuropaBio and the Spanish Bioindustry Association (ASEBIO), ... physicians from Spanish oncology and rheumatology societies, representatives ...
(Date:11/26/2014)... Charlotte, NC (PRWEB) November 25, 2014 ... High Intensity Focused Ultrasound (HIFU) devices, recently participated ... “ Small Renal Mass 360° .” Key opinion ... and therapeutic advances related to small renal masses ... learn about different ablative technologies in hands-on labs. ...
(Date:11/26/2014)... Chester, OH (PRWEB) November 25, 2014 ... Holdings, has joined the Graphel Carbon Products team as ... in sales, marketing, and customer service for the graphite ... add Miles to our team,” stated Dave Trinkley, VP ... “His wide range of experience in the graphite ...
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) announced today ... serve in a newly created position of Senior Vice ... be responsible for managing the operations of Bio-Techne,s Protein ... in July 2014 and the recently acquired CyVek business. ... ProteinSimple develops and commercializes proprietary systems and consumables that ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
Cached News: